OSU6162 as a potential novel drug treatment for Parkinson's disease: effects on dopamine D2 receptor binding in human brain studied using PET.

OSU6162 as a potential novel drug treatment for Parkinson's disease: effects on dopamine D2 receptor binding in human brain studied using PET. - Effects of OSU6162 on dopamine D2 receptor binding in human brain.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36314

Enrollment

Registered

2011-03-29

Start date

2011-07-22

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinsons disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Investigational group: healthy volunteers (males) Age between 50-60 years Good physical health evaluated by medical history, physical (including neurological) examination RDC (Research Diagnostic Criteria) diagnosis never mentally ill

Exclusion criteria

Exclusion criteria: Exclusion criteria include a history of a neurological or psychiatric disorder, the use of any centrally active medication, drug abuse (a toxicology screening of urine will be performed to detect opiates, cocaine, amphetamines, cannabis, methadone, benzodiazepines and barbiturates), and participation in other studies involving radiation exposure.

Design outcomes

Primary

Measure	Time frame
Striatal binding potential (BPND) values will be used as outcome measure. Striatal D2 receptor occupancy (%) will be calculated according to: occupancy = 100 * (1 * BPOSU/BPbaseline).	—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results